Figures & data
Figure 1 Signal 1 is antigenic, whereas signal 2 is costimulatory from the antigen-presenting cell.
Note: Following costimulation, cytokines such as interleukin-2 drive T-cell division, causing clonal expansion.
Abbreviations: MHC, major histocompatibility complex; TCR, T-cell receptor.
Abbreviations: MHC, major histocompatibility complex; TCR, T-cell receptor.
Figure 2 All patients received induction with basiliximab and maintenance therapy with mycophenolate mofetil and corticosteroids.
Notes: Patients randomized to receive cyclosporine were started at 7 ± 3 mg/kg daily in divided doses with a goal trough of 150–300 ng/mL for the first month followed by 100–250 ng/mL thereafter. MI-treated patients received belatacept at 10 mg/kg for the first 168 days and 5 mg/kg from day 196 onwards. LI-treated patients received belatacept at 10 mg/kg for the first 84 days and 5 mg/kg from day 112 onward. *All patients received basilixmab induction, mycophenolate mofetil, and corticosteroid-taper.
Figure 3 Measured glomerular filtration rate (GFR) by month 12 in patients with and without rejection in BENEFIT.
Abbreviations: AR, acute rejection; BENEFIT, Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial; CsA, cyclosporine; LI, less intensive; MI, more intensive.
Figure 4 Percentage of patients at chronic kidney disease stages at 3 years in BENEFIT-EXT.
Abbreviation: BENEFIT-EXT, Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial-EXTended criteria donors.
Table 1 Incidence of malignancies and PTLD in the pooled analysis from the Phase II and III belatacept trials
Figure 5 Incidence of new-onset diabetes after transplant in BENEFIT and BENEFIT-EXT and in a pooled analysis of both studies.
Note: *P < 0.05 versus CsA.
Abbreviation: CsA, cyclosporine.
Abbreviation: CsA, cyclosporine.
